Veracyte, Inc.

We’re pleased to announce Veracyte has been #GreatPlaceToWork – CertifiedTM in the US and Israel. We’re honored to receive this recognition, reflecting our collaborative culture driving our mission. Thank you for making us who we are #TeamVeracyte!    🔎  Explore our Great Places to Work – Certified Company overview page: https://lnkd.in/gHVfSjpu      🤝  Learn more about our exceptional team and working at Veracyte:   https://lnkd.in/eiuur7cx      #GPTWcertified #employeeappreciation #workculture #lifeatVeracyte #employeeexperience #inspiredworkplace #pioneeringtogether #cultureofexcellence #workinIsrael #innovationculture #creativeecosystem #diverseworkplace  

From our #TeamVeracyte family to yours – thank you for making 2024 extraordinary! 🌟 To our incredible employees who fuel our progress, the physicians who trust our tests, and the partners who work with us to drive insights and evidence – thank you. Together we are transforming cancer care for patients around the world. 🌍 As we welcome 2025, we're grateful for each person who contributes to our mission of improving cancer care with exceptional diagnostics 🤍 Wishing you all moments of joy and meaningful connections this holiday season! #LifeSciences #Healthcare #Diagnostics 

We are grateful to have had the opportunity to work with Dr. Felix Feng on innovative trials and biomarker development. His impact to cancer patients was profound and will be long lived. He will be dearly missed. #ProstateCancerResearch #CancerResearch #Healthcare #Innovation

Thank you, Allison Gatlin and Investor's Business Daily, for your thoughtful coverage of Veracyte's growth story and our mission to improve patient care through innovative diagnostics. 🔗 Read more about how Veracyte is working to transform cancer diagnostics: https://lnkd.in/gtwq4kmv   #DecipherProstate #PrecisionMedicine #CancerDiagnostics #UrologicOncology #MolecularDiagnostics  

Among the nearly 300,000 patients in the United States diagnosed with prostate cancer each year,* those with low-risk characteristics, such as Gleason Grade Group 1 disease, may choose Active Surveillance (AS) where they are monitored without initial treatment to avoid treatment-related complications.       Mark I. Sultan, M.D., a clinical research assistant specialist at University of California Irvine, presented data at the Society of Urologic Oncology (#SUO24) last week showing that Decipher Prostate Genomic Classifier independently predicted prostate cancer progression, relative to multiparametric magnetic resonance imaging (mpMRI), in a large cohort of men with prostate cancer who were being managed with Active Surveillance (AS).     “Our results show that the Decipher Prostate test is an independent predictor of cancer progression in AS regardless of a patient’s risk on mpMRI, meaning that a Decipher test and a prostate mpMRI capture distinct, complementary prognostic information. These findings suggest that, when combined, the tests will provide a more comprehensive assessment of an individual’s cancer.”     Congratulations to Mark Sultan, M.D., and the UC Irvine team on their important research advancing precision medicine in prostate cancer care 👏   For more details on Dr. Sultan's presentation:    🔗 SUO Abstract: https://lnkd.in/gzTwnn9w     🔗 UroToday Coverage: https://lnkd.in/gcGu3Tuz      #UroOnc #PrecisionMedicine #ProstateCancer #ClinicalResearch #LifeSciences     This article contains forward-looking statements. These forward-looking statements involve risks and uncertainties. Please visit our website for more information https://lnkd.in/gpHMFcjH     *American Cancer Society. Cancer Facts & Figures 2024. Atlanta: American Cancer Society, 2024. 

Advancing precision medicine in breast cancer care takes dedication, innovation, and trusted partnerships. This week at #SABCS24, our Veracyte team is proud to showcase how the #Prosigna test is helping clinicians worldwide advance breast cancer treatment decisions. 📍Connect with us at booth #1243 and attend our in-booth focused medical discussions throughout #SABCS24. The full schedule of medical discussions is available at: https://lnkd.in/eEt_UQ9N   #PrecisionMedicine #CancerCare #Oncology #ClinicalResearch #BreastCancer #IntrinsicMolecularSubtypes  

🏆 Milestone achievement: The Decipher Prostate Genomic Classifier is now the only gene expression test with the Simon Level 1 evidence needed to be listed as an advanced tool for risk stratification of localized prostate cancer in the NCCN Clinical Practice Guidelines in Oncology* (NCCN Guidelines®) for prostate cancer. With validation from studies involving over 100,000 patients, this 22-gene test helps to arm physicians with extra information to help them make personalized treatment decisions. 🔗 Read the press release and learn more, https://lnkd.in/g7GdqhKR   *National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.  #PrecisionMedicine #ProstateCancer #Oncology #DecipherProstate 

Research Data Highlight: Findings from VANDAAM, the first-ever prospective clinical trial aimed at assessing the effectiveness of genomic prostate cancer risk-stratification in African American men, suggest #DecipherProstate could potentially play a role in reducing #prostatecancer outcome disparities, helping to advance more equitable care.     Learn more about this study and the importance and power of genomic testing.  https://lnkd.in/gapA3wrp      #MensHealthAwarenessMonth #menshealth #movember #prostatecancerawareness #prostatehealth #genomictesting #personalizedmedicine 

Data from an analysis of the STAMPEDE trial further highlights the important role of genomic testing in the cancer care journey. #DecipherProstate has the ability to provide clinicians with insights that can help guide more personalized treatment planning and ensure their patients receive the therapy they need.   💡Learn more about this study and the importance and power of genomic testing: https://lnkd.in/gapA3wrp   #MensHealthAwarenessMonth #menshealth #movember #prostatecancerawareness #prostatecancerresearch #bettertogether#researchcollaboration #prostatehealth

This #MensHealthAwarenessMonth, we're raising awareness about prostate cancer. In this blog post, our Chief Medical Officer, Phillip G. Febbo, MD, offers insights into the evolution of #prostatecancer care, the role of #genomictesting, and promising future of #personalizedmedicine.    ⚖️ What makes prostate cancer treatment decisions challenging.  🧬 How molecular assays are becoming a standard of care.  🌎 The use of personalized-medicine tools, such as Decipher Prostate, and the importance of ensuring new technologies benefit all patients, including diverse populations.    We invite you to read and share it here: https://lnkd.in/gkErJNhN      #menshealthmonth #menshealth #movember #prostatecancerawareness #prostatehealth #DecipherProstate